血清前白蛋白和总胆汁酸联合检测在慢性肝病中的临床价值

目的 研究血清前白蛋白总胆汁酸联合检测在慢性肝病中的临床价值。方法 分别采用免疫浊度法、酸循环法检测慢性肝病患者血清前白蛋白(PAB)和总胆汁酸(TBA)水平。结果 肝硬化组、肝炎组血清PAB水平较对照组均明显下降(P<0.01,P<0.05),而血清TBA较对照组均明显升高(P<0.01,P<0.05),肝炎组与肝硬化组血清PAB和TBA水平也均有显著差异(P<0.05,P<0,05),肝炎组内重度患者血清PAB水平较轻、中度明显降低(P<0.05)而血清TBA水平较轻中度患者明显升高(P<0.01,P<0.05);结论 血清PAB、TBA变化能敏感地反映肝脏合成和代谢功能及肝实质的损害程度,联合检测血清二者的变化,有助于慢性肝病的病情判断,更有利于指导临床治疗。

Clinical Significance and Assay of PAB、TBA in Chronic Hepatic Diseases

Objective To investigate the clinical significance of PAB and TBA in some chronic hepatic diseases. Methods The level of PAB was tasted by immunoturbidity method. And the level of TBA was detected by enzyme recycle method. Results The level of PAB in cirrhosis and hepatitis groups are both decreased (P<0.01,P<0.05), while TBA are both increased (P<0.01,P<0.05), And there's great difference between the two groups (P<0. 05). On the contrary, TBA is higher than the last two groups (P<0. 01,P<0.05). Conclusion The study suggests PAB and TBA can be sensitive index to hepatic metabolism and damage. It will be helpful for the diagnosis & treatment of chronic hepatic disease with the two items combined.